CA2605057A1 - Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi) - Google Patents

Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi) Download PDF

Info

Publication number
CA2605057A1
CA2605057A1 CA002605057A CA2605057A CA2605057A1 CA 2605057 A1 CA2605057 A1 CA 2605057A1 CA 002605057 A CA002605057 A CA 002605057A CA 2605057 A CA2605057 A CA 2605057A CA 2605057 A1 CA2605057 A1 CA 2605057A1
Authority
CA
Canada
Prior art keywords
tfpi
analog
ala
administration
dose rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605057A
Other languages
English (en)
Inventor
Abla Creasey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605057A1 publication Critical patent/CA2605057A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002605057A 2005-04-15 2006-04-14 Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi) Abandoned CA2605057A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67146605P 2005-04-15 2005-04-15
US60/671,466 2005-04-15
PCT/US2006/013890 WO2006113360A2 (fr) 2005-04-15 2006-04-14 Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi)

Publications (1)

Publication Number Publication Date
CA2605057A1 true CA2605057A1 (fr) 2006-10-26

Family

ID=36951247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605057A Abandoned CA2605057A1 (fr) 2005-04-15 2006-04-14 Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi)

Country Status (13)

Country Link
EP (1) EP1871408A2 (fr)
JP (1) JP2008536859A (fr)
KR (1) KR20080033151A (fr)
CN (1) CN101180074A (fr)
AU (1) AU2006236698A1 (fr)
BR (1) BRPI0610549A2 (fr)
CA (1) CA2605057A1 (fr)
IL (1) IL186548A0 (fr)
MX (1) MX2007012619A (fr)
RU (1) RU2007142192A (fr)
TN (1) TNSN07386A1 (fr)
WO (1) WO2006113360A2 (fr)
ZA (1) ZA200708700B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129164A1 (fr) * 2008-04-15 2009-10-22 Novartis Ag Combinaisons pharmaceutiques de fragments de tfpi et d'un antibiotique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501111A2 (en) * 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor

Also Published As

Publication number Publication date
CN101180074A (zh) 2008-05-14
ZA200708700B (en) 2008-12-31
EP1871408A2 (fr) 2008-01-02
JP2008536859A (ja) 2008-09-11
MX2007012619A (es) 2008-01-11
WO2006113360A3 (fr) 2007-04-12
KR20080033151A (ko) 2008-04-16
IL186548A0 (en) 2008-01-20
BRPI0610549A2 (pt) 2010-07-06
TNSN07386A1 (en) 2009-03-17
WO2006113360A2 (fr) 2006-10-26
AU2006236698A1 (en) 2006-10-26
RU2007142192A (ru) 2009-05-20

Similar Documents

Publication Publication Date Title
US7674769B2 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
US20090214506A1 (en) Use of TFPI to Treat Severe Bacterial Infections
AU2002340183A1 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
US20080286279A1 (en) Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
CA2605057A1 (fr) Traitement de la pneumonie aigue communautaire par l'administration d'un inhibiteur de la voie du facteur tissulaire (tfpi)
AU2007202500A1 (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)

Legal Events

Date Code Title Description
FZDE Discontinued